CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 170 filers reported holding CLOVIS ONCOLOGY INC in Q3 2016. The put-call ratio across all filers is 0.79 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $63,000 | -65.0% | 52,609 | -47.2% | 0.00% | – |
Q2 2022 | $180,000 | -90.9% | 99,690 | -89.8% | 0.00% | – |
Q1 2022 | $1,969,000 | +46.0% | 974,210 | +95.7% | 0.00% | – |
Q4 2021 | $1,349,000 | -41.4% | 497,877 | -3.6% | 0.00% | – |
Q3 2021 | $2,304,000 | -53.2% | 516,628 | -39.1% | 0.00% | -100.0% |
Q2 2021 | $4,919,000 | -1.8% | 848,171 | +18.9% | 0.00% | 0.0% |
Q1 2021 | $5,007,000 | +73.2% | 713,231 | +18.5% | 0.00% | +100.0% |
Q4 2020 | $2,891,000 | -33.0% | 602,078 | -18.6% | 0.00% | -50.0% |
Q3 2020 | $4,312,000 | -12.6% | 739,556 | +1.2% | 0.00% | -50.0% |
Q2 2020 | $4,931,000 | +14.8% | 730,500 | +8.2% | 0.00% | 0.0% |
Q1 2020 | $4,294,000 | -27.7% | 675,187 | +18.5% | 0.00% | -55.6% |
Q4 2019 | $5,939,000 | +5399.1% | 569,622 | +1959.8% | 0.01% | – |
Q3 2019 | $108,000 | -81.9% | 27,654 | -31.0% | 0.00% | -100.0% |
Q2 2019 | $596,000 | -70.4% | 40,086 | -50.6% | 0.00% | -66.7% |
Q1 2019 | $2,014,000 | -1.1% | 81,139 | -28.5% | 0.00% | -40.0% |
Q4 2018 | $2,037,000 | +86.5% | 113,409 | +204.9% | 0.01% | +150.0% |
Q3 2018 | $1,092,000 | -58.7% | 37,195 | -36.1% | 0.00% | -66.7% |
Q2 2018 | $2,645,000 | -49.5% | 58,178 | -41.4% | 0.01% | -57.1% |
Q1 2018 | $5,242,000 | +2.6% | 99,285 | +32.2% | 0.01% | 0.0% |
Q4 2017 | $5,107,000 | -42.9% | 75,101 | -30.8% | 0.01% | -50.0% |
Q3 2017 | $8,940,000 | -47.6% | 108,488 | -40.4% | 0.03% | -53.3% |
Q2 2017 | $17,046,000 | +220.7% | 182,054 | +118.0% | 0.06% | +160.9% |
Q1 2017 | $5,316,000 | +38.0% | 83,494 | -3.7% | 0.02% | +35.3% |
Q4 2016 | $3,851,000 | -19.1% | 86,700 | -34.3% | 0.02% | -26.1% |
Q3 2016 | $4,759,000 | +1656.1% | 132,006 | +568.0% | 0.02% | +2200.0% |
Q2 2016 | $271,000 | -78.2% | 19,762 | -69.5% | 0.00% | -85.7% |
Q1 2016 | $1,242,000 | +63.6% | 64,700 | +198.4% | 0.01% | +75.0% |
Q4 2015 | $759,000 | -84.5% | 21,682 | -59.3% | 0.00% | -86.7% |
Q3 2015 | $4,895,000 | +338.6% | 53,220 | +319.1% | 0.03% | +328.6% |
Q2 2015 | $1,116,000 | -85.4% | 12,700 | -87.7% | 0.01% | -88.1% |
Q1 2015 | $7,647,000 | – | 103,025 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |